Personal history of selected autoimmune disorders and pooled relative risk of non-Hodgkin lymphoma (NHL) by cell lineage (B-cell, T-cell, unknown cell lineage)
| Disorder* . | Controls: Ever/never . | Cases . | |||||
|---|---|---|---|---|---|---|---|
| B cell† (n = 10,723) . | T cell‡ (n = 745) . | Unknown cell lineage (n = 1514) . | |||||
| Ever/never . | OR (95% CI)§ . | Ever/never . | OR (95% CI)§ . | Ever/never . | OR (95% CI)† . | ||
| Psoriasis | 279/10 122 | 231/5971 | 1.11 (0.92-1.33) | 22/351 | 1.63 (1.03-2.57) | 25/1138 | 1.30 (0.83-2.03) |
| Ulcerative colitis | 138/12 148 | 96/7996 | 1.04 (0.79-1.37) | 8/504 | 1.53 (0.73-3.21) | 21/1275 | 0.96 (0.59-1.56) |
| Type 1 diabetes | 58/13 613 | 29/8430 | 0.85 (0.53-1.35) | 0/564 | ND | 3/1295 | 0.56 (0.17-1.86) |
| Sarcoidosis | 27/8856 | 14/6627 | 0.61 (0.32-1.18) | 4/465 | 2.49 (0.85-0.27) | 1/515 | 0.66 (0.08-0.17) |
| Pernicious anemia | 16/5865 | 13/2719 | 1.32 (0.61-2.84) | 0/153 | ND | 0/538 | ND |
| Crohn disease | 27/10 614 | 17/7726 | 0.79 (0.421-.47) | 2/494 | 1.47 (0.34-6.35) | 4/1010 | 1.58 (0.52-0.78) |
| Celiac disease | 25/10 424 | 22/7916 | 1.16 (0.652-.08) | 9/554 | 6.21 (2.82-13.6) | 2/873 | 1.66 (0.36-7.62) |
| Hemolytic anemia | 13/5585 | 17/2466 | 2.62 (1.25-5.52) | 1/176 | 2.08 (0.24-17.7) | 3/600 | 2.32 (0.63-8.53) |
| Systemic lupus erythematosus | 26/15 237 | 45/9886 | 2.44 (1.49-3.99) | 3/669 | 2.43 (0.72-8.24) | 9/1479 | 4.53 (2.00-10.3) |
| Multiple sclerosis | 18/12 341 | 14/8172 | 1.06 (0.52-2.16) | 0/594 | ND | 1/900 | 0.80 (0.10-6.33) |
| Sjögren syndrome | 8/10 543 | 45/6800 | 6.52 (3.061-3.93) | 1/505 | 2.03 (0.25-16.6) | 6/873 | 16.3 (4.70-56.4) |
| Primary Sjögren syndrome | 5/10 543 | 21/6798 | 4.97 (1.86-13.29) | 0/505 | ND | 2/873 | 5.54 (0.87-35.5) |
| Secondary Sjögren syndrome | 3/10 542 | 24/6800 | 9.11 (2.72-30.46) | 1/505 | 5.13 (0.51-51.8) | 4/873 | 37.7 (7.38-192) |
| Disorder* . | Controls: Ever/never . | Cases . | |||||
|---|---|---|---|---|---|---|---|
| B cell† (n = 10,723) . | T cell‡ (n = 745) . | Unknown cell lineage (n = 1514) . | |||||
| Ever/never . | OR (95% CI)§ . | Ever/never . | OR (95% CI)§ . | Ever/never . | OR (95% CI)† . | ||
| Psoriasis | 279/10 122 | 231/5971 | 1.11 (0.92-1.33) | 22/351 | 1.63 (1.03-2.57) | 25/1138 | 1.30 (0.83-2.03) |
| Ulcerative colitis | 138/12 148 | 96/7996 | 1.04 (0.79-1.37) | 8/504 | 1.53 (0.73-3.21) | 21/1275 | 0.96 (0.59-1.56) |
| Type 1 diabetes | 58/13 613 | 29/8430 | 0.85 (0.53-1.35) | 0/564 | ND | 3/1295 | 0.56 (0.17-1.86) |
| Sarcoidosis | 27/8856 | 14/6627 | 0.61 (0.32-1.18) | 4/465 | 2.49 (0.85-0.27) | 1/515 | 0.66 (0.08-0.17) |
| Pernicious anemia | 16/5865 | 13/2719 | 1.32 (0.61-2.84) | 0/153 | ND | 0/538 | ND |
| Crohn disease | 27/10 614 | 17/7726 | 0.79 (0.421-.47) | 2/494 | 1.47 (0.34-6.35) | 4/1010 | 1.58 (0.52-0.78) |
| Celiac disease | 25/10 424 | 22/7916 | 1.16 (0.652-.08) | 9/554 | 6.21 (2.82-13.6) | 2/873 | 1.66 (0.36-7.62) |
| Hemolytic anemia | 13/5585 | 17/2466 | 2.62 (1.25-5.52) | 1/176 | 2.08 (0.24-17.7) | 3/600 | 2.32 (0.63-8.53) |
| Systemic lupus erythematosus | 26/15 237 | 45/9886 | 2.44 (1.49-3.99) | 3/669 | 2.43 (0.72-8.24) | 9/1479 | 4.53 (2.00-10.3) |
| Multiple sclerosis | 18/12 341 | 14/8172 | 1.06 (0.52-2.16) | 0/594 | ND | 1/900 | 0.80 (0.10-6.33) |
| Sjögren syndrome | 8/10 543 | 45/6800 | 6.52 (3.061-3.93) | 1/505 | 2.03 (0.25-16.6) | 6/873 | 16.3 (4.70-56.4) |
| Primary Sjögren syndrome | 5/10 543 | 21/6798 | 4.97 (1.86-13.29) | 0/505 | ND | 2/873 | 5.54 (0.87-35.5) |
| Secondary Sjögren syndrome | 3/10 542 | 24/6800 | 9.11 (2.72-30.46) | 1/505 | 5.13 (0.51-51.8) | 4/873 | 37.7 (7.38-192) |
ND indicates not determined.
Restricted to a history of the autoimmune disorder diagnosed at least 2 years before interview/NHL diagnosis.
Apart from subgroups of patients displayed in Table 6, patients with B-cell NHL also included 289 patients with lymphoplasmacytic lymphoma, 116 with hairy-cell leukemia, 106 with Burkitt lymphoma, 24 with precursor B-cell lymphoma, and 927 with unspecified B-cell NHL (see also Table S1).
The T-cell NHL group consisted of 389 patients with peripheral T-cell NHL (127 with anaplastic large cell lymphoma, 20 with cutaneous T-cell lymphoma not otherwise specified, 14 with primary cutaneous anaplastic large cell lymphoma, 53 with angioimmunoblastic, 19 with enteropathy-type, 4 with subcutaneous panniculitis-like, 2 with hepatosplenic T-cell lymphoma, and 150 with other peripheral T-cell NHLs), 29 with precursor T-cell NHL, 19 with NK/T-cell lymphoma nasal type or aggressive NK-cell leukemia, 7 with T-cell large granular lymphocytic leukemia, 7 with T-cell prolymphocytic leukemia and 44 with unspecified T-cell NHL (see also Table S1).
Odds ratios (OR) and 95% confidence intervals (CI) computed using a joint-fixed effects model adjusted for age (in 5-year categories), sex, race/ethnicity, education/SES, and study center, with no history of the autoimmune disease in question as reference category.